Literature DB >> 15170358

Effector-mediated alteration of substrate orientation in cytochrome P450 2C9.

Matthew A Hummel1, Peter M Gannett, Jarrett S Aguilar, Timothy S Tracy.   

Abstract

Cytochrome P450 2C9 (CYP2C9)-mediated flurbiprofen 4'-hydroxylation is activated by the presence of dapsone resulting in reduction of the K(m) for flurbiprofen hydroxylation and an increase in V(m). Previous spectral binding studies have demonstrated that the binding of flurbiprofen with CYP2C9 is increased (decrease in K(S)) by the presence of dapsone. We hypothesized that the two compounds are simultaneously in the active site with the presence of dapsone causing flurbiprofen to be oriented more closely to the heme. T(1) relaxation rates determined by NMR were used to estimate the distances of protons on these compounds from the paramagnetic heme-iron center. Samples contained 0.014 microM CYP2C9 and 145 microM flurbiprofen in the presence and absence of 100 microM dapsone. Estimated distances of various flurbiprofen protons from the heme ranged from 4.2 to 4.5 A in the absence of dapsone and from 3.2 to 3.8 A in the presence of dapsone. The 4' proton of flurbiprofen, the site of metabolism, showed one of the greatest differences in distance from the heme in the presence of dapsone, 3.50 A, as compared to the absence of dapsone, 4.41 A. Dapsone protons were less affected, being 4.40 A from the heme in the absence of flurbiprofen and 4.00-4.01 A from the heme in the presence of flurbiprofen. Molecular modeling studies were also performed to corroborate the relative orientations of flurbiprofen and dapsone in the active site of CYP2C9. Shift of the 4' proton of flurbiprofen closer to the heme iron of CYP2C9 in the presence of dapsone may play a role in activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15170358     DOI: 10.1021/bi036158o

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  16 in total

1.  Multiple ligand docking by Glide: implications for virtual second-site screening.

Authors:  Márton Vass; Ákos Tarcsay; György M Keserű
Journal:  J Comput Aided Mol Des       Date:  2012-05-26       Impact factor: 3.686

2.  CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant.

Authors:  Matthew A Hummel; Charles W Locuson; Peter M Gannett; Dan A Rock; Carrie M Mosher; Allan E Rettie; Timothy S Tracy
Journal:  Mol Pharmacol       Date:  2005-06-13       Impact factor: 4.436

Review 3.  Substrate binding to cytochromes P450.

Authors:  Emre M Isin; F Peter Guengerich
Journal:  Anal Bioanal Chem       Date:  2008-07-13       Impact factor: 4.142

4.  Role of subunit interactions in P450 oligomers in the loss of homotropic cooperativity in the cytochrome P450 3A4 mutant L211F/D214E/F304W.

Authors:  Harshica Fernando; Dmitri R Davydov; Christopher C Chin; James R Halpert
Journal:  Arch Biochem Biophys       Date:  2007-01-12       Impact factor: 4.013

5.  Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone.

Authors:  Matthew A Hummel; Peter M Gannett; Jarrett Aguilar; Timothy S Tracy
Journal:  Arch Biochem Biophys       Date:  2008-05-01       Impact factor: 4.013

6.  NMR-derived models of amidopyrine and its metabolites in complexes with rabbit cytochrome P450 2B4 reveal a structural mechanism of sequential N-dealkylation.

Authors:  Arthur G Roberts; Sara E A Sjögren; Nadezda Fomina; Kathy T Vu; Adah Almutairi; James R Halpert
Journal:  Biochemistry       Date:  2011-03-04       Impact factor: 3.162

7.  Preferred binding orientations of phenacetin in CYP1A1 and CYP1A2 are associated with isoform-selective metabolism.

Authors:  Qingbiao Huang; Rahul S Deshmukh; Spencer S Ericksen; Youbin Tu; Grazyna D Szklarz
Journal:  Drug Metab Dispos       Date:  2012-09-04       Impact factor: 3.922

8.  Preparation, characterization, and substrate metabolism of gold-immobilized cytochrome P450 2C9.

Authors:  Peter M Gannett; Jarod Kabulski; Felio A Perez; Zhongyuan Liu; David Lederman; Charles W Locuson; Robyn R Ayscue; Nissa M Thomsen; Timothy S Tracy
Journal:  J Am Chem Soc       Date:  2006-07-05       Impact factor: 15.419

9.  Mechanism of interactions of alpha-naphthoflavone with cytochrome P450 3A4 explored with an engineered enzyme bearing a fluorescent probe.

Authors:  Tamara N Tsalkova; Nadezhda Y Davydova; James R Halpert; Dmitri R Davydov
Journal:  Biochemistry       Date:  2007-01-09       Impact factor: 3.162

10.  Structures of cytochrome P450 2B4 complexed with the antiplatelet drugs ticlopidine and clopidogrel .

Authors:  Sean C Gay; Arthur G Roberts; Keiko Maekawa; Jyothi C Talakad; Wen-Xu Hong; Qinghai Zhang; C David Stout; James R Halpert
Journal:  Biochemistry       Date:  2010-09-15       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.